Tearsheet

Exponent (EXPO)


Market Price (4/19/2026): $68.04 | Market Cap: $3.4 Bil
Sector: Industrials | Industry: Research & Consulting Services

Exponent (EXPO)


Market Price (4/19/2026): $68.04
Market Cap: $3.4 Bil
Sector: Industrials
Industry: Research & Consulting Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 21%

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 23%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 21%

Low stock price volatility
Vol 12M is 29%

Megatrend and thematic drivers
Megatrends include Advanced Materials, Electric Vehicles & Autonomous Driving, and Automation & Robotics. Themes include Lightweight Composites, Show more.

Weak multi-year price returns
2Y Excs Rtn is -50%, 3Y Excs Rtn is -102%

Key risks
EXPO key risks include [1] its dependence on attracting and retaining highly specialized personnel, Show more.

0 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 21%
1 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 23%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 21%
2 Low stock price volatility
Vol 12M is 29%
3 Megatrend and thematic drivers
Megatrends include Advanced Materials, Electric Vehicles & Autonomous Driving, and Automation & Robotics. Themes include Lightweight Composites, Show more.
4 Weak multi-year price returns
2Y Excs Rtn is -50%, 3Y Excs Rtn is -102%
5 Key risks
EXPO key risks include [1] its dependence on attracting and retaining highly specialized personnel, Show more.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Exponent (EXPO) stock has remained largely at the same level since 12/31/2025 because of the following key factors:

1. Overall Economic Headwinds Impacted the Consulting Sector.

Exponent operates within the broader consulting industry, which experienced "continued economic uncertainty" in early 2026. This was evidenced by a downward revision of Q4 2025 U.S. GDP growth to 0.7% annualized from an initial 1.4% estimate. A softening labor market, with nonfarm payrolls declining by 92,000 in February 2026, also contributed to a cautious economic outlook. These macroeconomic factors led to clients exhibiting "greater price sensitivity, and hesitancy to launch new initiatives," impacting demand across the consulting sector.

2. Increased Competition and Shifting Client Demands.

The consulting industry is facing a more competitive landscape in 2026 due to an influx of professionals entering the field. Concurrently, client expectations are evolving, with a growing emphasis on measurable return on investment (ROI), tighter project scopes, and faster delivery of value. This has also driven a trend towards clients developing more in-house capabilities and increasing procurement scrutiny, potentially reducing reliance on external consultants. These pressures can affect pricing and the volume of work secured by firms like Exponent.

Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -1.6% change in EXPO stock from 12/31/2025 to 4/18/2026 was primarily driven by a -3.8% change in the company's P/E Multiple.
(LTM values as of)123120254182026Change
Stock Price ($)69.1768.05-1.6%
Change Contribution By: 
Total Revenues ($ Mil)5715821.9%
Net Income Margin (%)18.3%18.2%-0.7%
P/E Multiple33.632.3-3.8%
Shares Outstanding (Mil)51501.2%
Cumulative Contribution-1.6%

LTM = Last Twelve Months as of date shown

Market Drivers

12/31/2025 to 4/18/2026
ReturnCorrelation
EXPO-1.6% 
Market (SPY)-5.4%40.9%
Sector (XLI)11.9%27.8%

Fundamental Drivers

The -1.2% change in EXPO stock from 9/30/2025 to 4/18/2026 was primarily driven by a -5.9% change in the company's P/E Multiple.
(LTM values as of)93020254182026Change
Stock Price ($)68.9168.05-1.2%
Change Contribution By: 
Total Revenues ($ Mil)5615823.8%
Net Income Margin (%)18.3%18.2%-0.7%
P/E Multiple34.332.3-5.9%
Shares Outstanding (Mil)51501.8%
Cumulative Contribution-1.2%

LTM = Last Twelve Months as of date shown

Market Drivers

9/30/2025 to 4/18/2026
ReturnCorrelation
EXPO-1.2% 
Market (SPY)-2.9%31.2%
Sector (XLI)12.9%28.7%

Fundamental Drivers

The -14.7% change in EXPO stock from 3/31/2025 to 4/18/2026 was primarily driven by a -13.9% change in the company's P/E Multiple.
(LTM values as of)33120254182026Change
Stock Price ($)79.7568.05-14.7%
Change Contribution By: 
Total Revenues ($ Mil)5595824.2%
Net Income Margin (%)19.5%18.2%-6.7%
P/E Multiple37.532.3-13.9%
Shares Outstanding (Mil)51501.9%
Cumulative Contribution-14.7%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2025 to 4/18/2026
ReturnCorrelation
EXPO-14.7% 
Market (SPY)16.3%41.0%
Sector (XLI)33.8%41.6%

Fundamental Drivers

The -28.9% change in EXPO stock from 3/31/2023 to 4/18/2026 was primarily driven by a -32.5% change in the company's P/E Multiple.
(LTM values as of)33120234182026Change
Stock Price ($)95.7268.05-28.9%
Change Contribution By: 
Total Revenues ($ Mil)51358213.4%
Net Income Margin (%)19.9%18.2%-8.6%
P/E Multiple47.832.3-32.5%
Shares Outstanding (Mil)51501.6%
Cumulative Contribution-28.9%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2023 to 4/18/2026
ReturnCorrelation
EXPO-28.9% 
Market (SPY)63.3%36.8%
Sector (XLI)78.8%42.9%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
EXPO Return31%-14%-10%2%-21%-2%-20%
Peers Return42%-3%19%9%-13%-5%48%
S&P 500 Return27%-19%24%23%16%3%87%

Monthly Win Rates [3]
EXPO Win Rate58%42%50%75%33%75% 
Peers Win Rate63%52%55%63%52%60% 
S&P 500 Win Rate75%42%67%75%67%50% 

Max Drawdowns [4]
EXPO Max Drawdown-8%-30%-28%-15%-26%-7% 
Peers Max Drawdown-4%-20%-7%-7%-24%-13% 
S&P 500 Max Drawdown-1%-25%-1%-2%-15%-7% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: TTEK, J, ACM, ICFI, FCN. See EXPO Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/17/2026 (YTD)

How Low Can It Go

Unique KeyEventEXPOS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-43.5%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven77.0%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-27.9%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven38.8%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven127 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-14.4%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven16.8%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven55 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-46.2%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven85.8%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven648 days1,480 days

Compare to TTEK, J, ACM, ICFI, FCN

In The Past

Exponent's stock fell -43.5% during the 2022 Inflation Shock from a high on 12/8/2021. A -43.5% loss requires a 77.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Exponent (EXPO)

Exponent, Inc., together with its subsidiaries, operates as a science and engineering consulting company worldwide. It operates in two segments, Engineering and Other Scientific, and Environmental and Health. The Engineering and Other Scientific segment provides services in the areas of biomechanics, biomedical engineering and sciences, buildings and structures, civil engineering, construction consulting, data sciences, electrical engineering and computer science, human factors, materials and corrosion engineering, mechanical engineering, polymer science and materials chemistry, thermal sciences, and vehicle engineering. The Environmental and Health segment offers services in the areas of chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences, and health sciences. The company offers approximately 90 technical disciplines to solve pressing and complicated challenges facing stakeholders. It serves clients in chemical, construction, consumer products, energy, food, beverage and nutrition, government, life sciences, insurance, manufacturing, technology, industrial equipment, transportation, and other sectors of the economy. The company was formerly known as The Failure Group, Inc. and changed its name to Exponent, Inc. in 1998. Exponent, Inc. was founded in 1967 and is headquartered in Menlo Park, California.

AI Analysis | Feedback

Here are 1-3 brief analogies for Exponent (EXPO):

  • Exponent is like **McKinsey or Boston Consulting Group, but for highly specialized scientific and engineering challenges.**
  • Think of Exponent as the **Mayo Clinic for complex industrial and scientific problems** that require deep expert analysis.

AI Analysis | Feedback

  • Engineering and Scientific Consulting: Provides expert consulting services across various engineering and scientific disciplines, including biomechanics, civil, electrical, mechanical, and data sciences, to solve complex technical challenges.
  • Environmental and Health Consulting: Offers specialized consulting services in areas such as chemical regulation, food safety, ecological sciences, and environmental and public health matters.

AI Analysis | Feedback

Exponent, Inc. (EXPO) primarily sells its science and engineering consulting services to other companies, government entities, and various organizations, rather than to individuals. Due to the nature of its diversified consulting business, Exponent typically serves a broad range of clients across numerous industries, and its public filings generally indicate that no single client accounts for a significant percentage of its consolidated revenues (e.g., 10% or more). Therefore, specific "major customer companies" by name are not publicly disclosed. However, Exponent identifies its customer base by the sectors it serves. These major client categories include:
  • Chemical
  • Construction
  • Consumer Products
  • Energy
  • Food, Beverage and Nutrition
  • Government
  • Life Sciences
  • Insurance
  • Manufacturing
  • Technology
  • Industrial Equipment
  • Transportation

AI Analysis | Feedback

null

AI Analysis | Feedback

Catherine Corrigan, Ph.D.
President and Chief Executive Officer

Dr. Catherine Corrigan joined Exponent in 1996, focusing on the biomechanics of human injury. She was appointed President of the company in 2016 and Chief Executive Officer in 2018. Prior to her role as CEO, she held positions as Principal in the Biomechanics Practice, Corporate Vice President, and Vice President of Exponent's Transportation Group. She holds a Ph.D. in Medical Engineering from the Harvard-MIT Division of Health Sciences and Technology, an M.S. in Mechanical Engineering from MIT, and a B.S. in Bioengineering from the University of Pennsylvania. Before joining Exponent, Dr. Corrigan was a researcher at the Orthopedic Biomechanics Laboratory of Beth Israel Hospital and Harvard Medical School.

Richard Schlenker
Executive Vice President and Chief Financial Officer

Mr. Richard Schlenker joined Exponent in October 1990. He has served in various finance and accounting positions within the company, including Business Manager for Exponent Failure Analysis Associates, Manager of Corporate Development, and Director of Corporate Development. He was appointed Corporate Secretary in November 1997 and became Chief Financial Officer in July 1999. Mr. Schlenker holds a B.S. in Finance from the University of Southern California.

Brian Kundert
Chief Human Resources Officer

Mr. Brian Kundert serves as the Chief Human Resources Officer for Exponent.

Subbaiah Malladi, Ph.D., P.E.
Chief Technical Officer and Principal Engineer

Dr. Subbaiah Malladi has been the Chief Technical Officer of Exponent Inc. since October 1998. He also serves as a Principal Engineer.

Ellen Donovan, MPH
Vice President, Business Development

Ms. Ellen Donovan holds the position of Vice President, Business Development at Exponent.

AI Analysis | Feedback

The key risks to Exponent, Inc. (symbol: EXPO) are primarily centered around its human capital, the competitive landscape of the consulting industry, and its revenue concentration in specific sectors.

  1. Reliance on Highly Skilled Personnel: Exponent's business model is fundamentally dependent on its ability to attract and retain a substantial workforce of highly skilled scientists and engineers, many of whom hold advanced degrees. The company reported employing 949 technical staff, with 731 holding doctorates as of January 2, 2026. A failure to attract and retain these critical employees could significantly impair the company's ability to deliver its specialized consulting services.
  2. Increasing Competition: The consulting market in which Exponent operates is characterized by high competition and relatively low barriers to entry. The company acknowledges growing competition, including from new entrants leveraging artificial intelligence technologies. This competitive environment can exert pressure on Exponent to continuously innovate, maintain service quality, and manage pricing effectively.
  3. Dependence on Key Industries and Volatile Demand: While Exponent serves a diverse range of sectors, a significant portion of its revenue is concentrated in a few key industries. In 2025, the consumer products, energy and utilities, transportation, and chemical industries collectively accounted for 68% of its total revenues, exposing the company to sector-specific risks and market fluctuations. Additionally, the demand for Exponent's services can be volatile and event-driven, which may lead to fluctuations in engagement timing and revenue.

AI Analysis | Feedback

null

AI Analysis | Feedback

Exponent, Inc. (symbol: EXPO) operates in diverse science and engineering consulting sectors. The addressable markets for its main products and services can be estimated as follows:

Engineering and Other Scientific Segment

  • Overall Engineering Consulting Services:
    • The global engineering consulting services market was valued at approximately USD 202.8 billion in 2025 and is projected to reach USD 296.2 billion by 2035, growing at a Compound Annual Growth Rate (CAGR) of 4.3% from 2026 to 2035.
    • Another estimate for the global engineering services market size indicated USD 2.34 trillion in 2025, with a projection to grow to USD 5.37 trillion by 2034, exhibiting a CAGR of 10.60% from 2026 to 2034.
    • North America is a dominant region within this market, anticipated to capture 39.5% of the global engineering consulting services market by 2035.
  • Biomedical Engineering/Bioengineering Technology:
    • The global Bioengineering Technology Market, which includes biomedical engineering, was valued at USD 301.53 billion in 2024 and is expected to reach approximately USD 762.73 billion by 2032, growing at a CAGR of 12.3% from 2025 to 2032.
  • Medical Device Engineering Services:
    • The global medical device engineering services market is estimated to be valued at USD 6.30 billion in 2025 and is expected to reach USD 13.68 billion by 2032, exhibiting a CAGR of 11.7% from 2025 to 2032.
    • Another source valued the global medical device engineering market at US$9.0 billion in 2024, projected to advance at a CAGR of 10.1% from 2024 to 2029, reaching US$14.7 billion by the end of the period.
    • North America is expected to maintain its leadership, holding 35.2% of the market share in 2025.
  • Human Biomechanics Analysis Software:
    • The global human biomechanics analysis software market size is estimated to be USD 350 million in 2024, projected to reach approximately USD 600 million by 2029, representing a CAGR of around 12%.
    • Another estimate places the market at USD 500 million in 2025, projected to reach approximately USD 1.5 billion by 2033, with a CAGR of 15% from 2025 to 2033.
    • North America currently holds the largest share in this market.

Environmental and Health Segment

  • Environmental Consulting Services:
    • The global environmental consulting services market was valued at US$ 43.04 billion in 2023 and is anticipated to reach US$ 77.35 billion by 2031, growing at a CAGR of 7.6% from 2023 to 2031.
    • Another report estimated the global environmental consulting services market size at USD 43.20 billion in 2024, predicted to increase to USD 92.85 billion by 2034, expanding at a CAGR of 7.95% from 2025 to 2034.
    • North America is expected to continue its dominance in the environmental consulting services market, holding a 35.53% revenue share in 2025.
  • Healthcare Consulting Services:
    • The global healthcare consulting services market was estimated at USD 28.19 billion in 2023 and is projected to reach USD 51.98 billion by 2030, growing at a CAGR of 9.33% from 2024 to 2030.
    • Another estimate places the global healthcare consulting services market size at USD 36.44 billion in 2025, predicted to increase to approximately USD 79.41 billion by 2035, expanding at a CAGR of 8.10% from 2026 to 2035.
    • North America dominated the healthcare consulting services market, holding 38.14% of the market share in 2023. In 2025, North America accounted for 48% of the revenue share.
  • Life Sciences Consulting Market:
    • The global Life Sciences Consulting Market size is expected to grow from USD 34.75 billion in 2025 to USD 38.02 billion in 2026 and is forecast to reach USD 59.64 billion by 2031, at a 9.42% CAGR from 2026 to 2031.
    • The global life science consulting market size was calculated at US$ 34.82 billion in 2024, grew to US$ 38.08 billion in 2025, and is projected to reach around US$ 84.83 billion by 2034.
    • North America dominated the life science consulting market in 2024.

AI Analysis | Feedback

Exponent (EXPO) is expected to drive future revenue growth over the next 2-3 years through several key factors:

  1. Consistent High-Single-Digit Revenue Growth and Price Increases: Management anticipates high-single-digit revenue growth for fiscal year 2026 and beyond, with expectations of reaching low double-digit growth in subsequent years. Additionally, Exponent projects realized rate increases of 3% to 3.5% for the first quarter and full year 2026.
  2. Growing Demand in Strategic Sectors and Macro Trends: The company is strategically positioned to capitalize on increasing demand across several industries and macro trends. Key drivers include the transportation sector (automation and electrification), the utilities sector (grid modernization, wildfire mitigation, aging infrastructure, and increased energy demand fueled by AI and data center investments), and consumer electronics (product safety, sustainability, and AI-driven product development). Furthermore, opportunities in life sciences and chemicals are expected to contribute to growth due to ongoing needs for safety, health, and environmental consulting services.
  3. Headcount Expansion and Optimized Utilization Rates: Exponent achieved approximately 4% headcount growth in 2025 and demonstrated improved utilization rates in Q4 2025, indicating an effective alignment of resources with market demand. The company aims for a long-term target of sustained mid-70s utilization, which is expected to enhance operational efficiency and support revenue expansion.
  4. Leveraging Multidisciplinary Expertise and Proactive Consulting Services: Exponent's distinctive ability to assemble specialized multidisciplinary teams to address complex challenges, coupled with an increased focus on proactive risk management and advisory services, particularly in the utility sector and through AI-related consulting, is a significant growth driver. This strategic emphasis on its unique expertise and forward-looking solutions strengthens its competitive advantage and expands its service offerings.

AI Analysis | Feedback

Capital Allocation Decisions (Last 3-5 Years) for Exponent (EXPO)

Share Repurchases

  • Exponent's Board of Directors authorized an additional $100 million for its share repurchase program in October 2025, bringing the total available for future repurchases to $121.6 million as of October 3, 2025.
  • During fiscal year 2025, Exponent repurchased $97.8 million of common stock.
  • In the first half of 2025, the company repurchased $32.7 million of common stock, including $27.7 million in the second quarter alone.

Share Issuance

  • A company Vice President converted 5,934 vested Restricted Stock Units (RSUs) into common stock on March 11, 2026, with 2,384 shares subsequently withheld by the company to cover tax obligations.
  • The number of common shares outstanding decreased from 52,116,161 as of February 18, 2022, to 50,642,422 as of February 17, 2023, indicating a net reduction in outstanding shares over that period.

Capital Expenditures

  • Capital expenditures for the full year 2025 were expected to be between $10 million and $12 million.
  • In the second quarter of 2025, capital expenditures amounted to $2.3 million.
  • The purchase of property, plant, and equipment was approximately $2.69 million in the fourth quarter of 2025.

Better Bets vs. Exponent (EXPO)

Trade Ideas

Select ideas related to EXPO.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
NSP_3312026_Insider_Buying_45D_2Buy_200K03312026NSPInsperityInsiderInsider Buys 45DStrong Insider Buying
Companies with multiple insider buys in the last 45 days
0.0%0.0%0.0%
TNC_3312026_Insider_Buying_45D_2Buy_200K03312026TNCTennantInsiderInsider Buys 45DStrong Insider Buying
Companies with multiple insider buys in the last 45 days
0.0%0.0%0.0%
ADP_3272026_Dip_Buyer_FCFYield03272026ADPAutomatic Data ProcessingDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
1.0%1.0%0.0%
HURN_3272026_Dip_Buyer_FCFYield03272026HURNHuron ConsultingDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
4.0%4.0%0.0%
TRU_3272026_Dip_Buyer_FCFYield03272026TRUTransUnionDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
5.2%5.2%0.0%
EXPO_2292020_Quality_Momentum_RoomToRun_10%02292020EXPOExponentQualityQ | Momentum | UpsideQuality Stocks with Momentum and Upside
Buying quality stocks with strong momentum but still having room to run
12.4%32.3%-19.2%

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

EXPOTTEKJACMICFIFCNMedian
NameExponent Tetra Te.Jacobs S.AECOM ICF Inte.FTI Cons. 
Mkt Price68.0531.61128.9386.6170.53179.5078.57
Mkt Cap3.48.215.311.31.35.46.8
Rev LTM5825,23312,39015,9561,8733,7894,511
Op Inc LTM1206008881,071145414507
FCF LTM12249887561612094310
FCF 3Y Avg124390824647133209300
CFO LTM132517960741142152335
CFO 3Y Avg135411932765155257334

Growth & Margins

EXPOTTEKJACMICFIFCNMedian
NameExponent Tetra Te.Jacobs S.AECOM ICF Inte.FTI Cons. 
Rev Chg LTM4.2%-2.9%6.6%-1.6%-7.3%2.4%0.4%
Rev Chg 3Y Avg4.3%15.1%7.0%6.5%2.0%7.9%6.8%
Rev Chg Q7.8%-14.8%12.3%-4.6%-10.6%10.7%1.6%
QoQ Delta Rev Chg LTM1.9%-3.9%3.0%-1.1%-2.7%2.6%0.4%
Op Inc Chg LTM0.2%11.8%17.0%13.5%-12.3%16.5%12.6%
Op Inc Chg 3Y Avg-4.5%19.8%14.8%14.4%11.6%10.5%13.0%
Op Mgn LTM20.6%11.5%7.2%6.7%7.8%10.9%9.4%
Op Mgn 3Y Avg20.9%10.1%6.5%6.0%7.6%10.5%8.8%
QoQ Delta Op Mgn LTM-0.1%0.4%-0.0%0.2%-0.2%0.6%0.1%
CFO/Rev LTM22.6%9.9%7.7%4.6%7.6%4.0%7.7%
CFO/Rev 3Y Avg24.1%8.0%8.4%4.9%7.9%7.0%7.9%
FCF/Rev LTM21.0%9.5%7.1%3.9%6.4%2.5%6.7%
FCF/Rev 3Y Avg22.1%7.5%7.4%4.1%6.8%5.7%7.1%

Valuation

EXPOTTEKJACMICFIFCNMedian
NameExponent Tetra Te.Jacobs S.AECOM ICF Inte.FTI Cons. 
Mkt Cap3.48.215.311.31.35.46.8
P/S5.91.61.20.70.71.41.3
P/Op Inc28.613.717.210.68.913.113.4
P/EBIT28.615.118.210.59.013.814.5
P/E32.323.435.324.214.120.123.8
P/CFO26.015.915.915.39.135.815.9
Total Yield4.9%5.1%3.3%5.4%7.9%5.0%5.0%
Dividend Yield1.8%0.8%0.5%1.2%0.8%0.0%0.8%
FCF Yield 3Y Avg3.0%4.2%5.1%4.9%6.5%3.2%4.6%
D/E0.00.10.20.30.40.10.2
Net D/E-0.00.10.10.20.40.10.1

Returns

EXPOTTEKJACMICFIFCNMedian
NameExponent Tetra Te.Jacobs S.AECOM ICF Inte.FTI Cons. 
1M Rtn4.5%2.3%0.7%-3.8%6.5%6.0%3.4%
3M Rtn-8.4%-15.0%-7.6%-11.5%-26.9%0.7%-9.9%
6M Rtn1.6%-3.0%-16.6%-33.4%-19.7%17.9%-9.8%
12M Rtn-11.6%5.3%12.2%-7.2%-14.4%8.6%-0.9%
3Y Rtn-27.4%14.5%39.9%8.0%-34.9%-9.2%-0.6%
1M Excs Rtn-2.1%-4.9%-6.7%-11.1%-1.2%1.2%-3.5%
3M Excs Rtn-10.7%-17.4%-11.3%-15.0%-29.7%-1.5%-13.1%
6M Excs Rtn-4.8%-9.2%-26.2%-41.2%-24.8%10.9%-17.0%
12M Excs Rtn-45.5%-25.9%-20.1%-38.8%-44.2%-23.3%-32.4%
3Y Excs Rtn-102.3%-61.5%-33.4%-65.6%-109.4%-85.7%-75.6%

Comparison Analyses

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Engineering and Other Scientific470447428381319
Environmental and Health8990858581
Total559537513466400


Operating Income by Segment
$ Mil20252024202320222021
Engineering and Other Scientific165154153140101
Environmental and Health3028272827
Corporate operating expense-75-71-39-59-44
Total12011114110983


Price Behavior

Price Behavior
Market Price$68.05 
Market Cap ($ Bil)3.4 
First Trading Date08/17/1990 
Distance from 52W High-14.4% 
   50 Days200 Days
DMA Price$68.86$70.17
DMA Trenddowndown
Distance from DMA-1.2%-3.0%
 3M1YR
Volatility41.0%29.4%
Downside Capture0.620.63
Upside Capture130.1277.01
Correlation (SPY)39.2%35.9%
EXPO Betas & Captures as of 3/31/2026

 1M2M3M6M1Y3Y
Beta-0.141.361.380.850.650.75
Up Beta-0.834.413.791.860.700.79
Down Beta-0.53-0.180.080.010.230.32
Up Capture-76%150%165%95%61%51%
Bmk +ve Days7162765139424
Stock +ve Days8192758114356
Down Capture65%131%142%103%108%103%
Bmk -ve Days12233358110323
Stock -ve Days14233668138395

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with EXPO
EXPO-13.5%29.2%-0.49-
Sector ETF (XLI)39.0%15.4%1.9335.7%
Equity (SPY)21.1%12.9%1.3236.4%
Gold (GLD)50.9%27.5%1.49-1.9%
Commodities (DBC)25.2%16.2%1.40-5.3%
Real Estate (VNQ)17.5%13.7%0.9329.9%
Bitcoin (BTCUSD)-7.8%42.6%-0.0826.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with EXPO
EXPO-6.7%29.7%-0.20-
Sector ETF (XLI)13.1%17.3%0.6049.9%
Equity (SPY)10.8%17.1%0.4946.6%
Gold (GLD)22.6%17.8%1.044.8%
Commodities (DBC)11.6%18.8%0.516.3%
Real Estate (VNQ)4.4%18.8%0.1448.2%
Bitcoin (BTCUSD)5.2%56.5%0.3120.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with EXPO
EXPO12.0%28.6%0.44-
Sector ETF (XLI)14.2%19.9%0.6351.5%
Equity (SPY)14.0%17.9%0.6751.4%
Gold (GLD)14.3%15.9%0.753.6%
Commodities (DBC)8.5%17.6%0.4014.7%
Real Estate (VNQ)5.6%20.7%0.2447.1%
Bitcoin (BTCUSD)68.4%66.9%1.0715.1%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date3312026
Short Interest: Shares Quantity3.2 Mil
Short Interest: % Change Since 315202611.6%
Average Daily Volume0.6 Mil
Days-to-Cover Short Interest5.8 days
Basic Shares Quantity50.3 Mil
Short % of Basic Shares6.4%

Earnings Returns History

Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
2/5/202612.6%-5.2%1.9%
10/30/20256.0%6.6%9.6%
7/31/2025-0.9%3.3%3.5%
5/1/2025-1.3%-0.8%-0.9%
2/6/20251.2%0.7%-6.0%
10/24/2024-8.9%-11.3%-7.8%
7/25/2024-0.6%-1.4%0.2%
4/25/202419.5%16.0%20.8%
...
SUMMARY STATS   
# Positive111012
# Negative131412
Median Positive3.6%5.5%8.0%
Median Negative-4.7%-6.1%-4.8%
Max Positive19.5%16.0%20.8%
Max Negative-14.4%-13.1%-12.5%

SEC Filings

Expand for More
Report DateFiling DateFiling
12/31/202502/27/202610-K
09/30/202511/07/202510-Q
06/30/202508/08/202510-Q
03/31/202505/09/202510-Q
12/31/202402/28/202510-K
09/30/202411/01/202410-Q
06/30/202408/02/202410-Q
03/31/202405/03/202410-Q
12/31/202302/23/202410-K
09/30/202311/03/202310-Q
06/30/202308/07/202310-Q
03/31/202305/05/202310-Q
12/31/202202/24/202310-K
09/30/202211/04/202210-Q
06/30/202208/05/202210-Q
03/31/202205/06/202210-Q

Recent Forward Guidance [BETA]

Latest: Q4 2025 Earnings Reported 2/5/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
Q1 2026 Revenue Growth 7.0% 75.0%3.0%RaisedGuidance: 4.0% for Q4 2025
Q1 2026 EBITDA Margin27.5%28.0%28.5%5.7%1.5%RaisedGuidance: 26.5% for Q4 2025
2026 Revenue Growth 7.0% 250.0%5.0%RaisedGuidance: 2.0% for 2025
2026 EBITDA Margin27.6%27.85%28.1%1.2%0.3%RaisedGuidance: 27.53% for 2025

Prior: Q3 2025 Earnings Reported 10/30/2025

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
Q4 2025 Revenue Growth1.0%4.0% -20.0%-1.0%LoweredGuidance: 5.0% for Q3 2025
Q4 2025 EBITDA Margin26.0%26.5%27.0%-2.8%-0.8%LoweredGuidance: 27.25% for Q3 2025
2025 Revenue Growth1.0%2.0% 00AffirmedGuidance: 2.0% for 2025
2025 EBITDA Margin27.4%27.53%27.65%2.9%0.8%RaisedGuidance: 26.75% for 2025

Insider Activity

Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Corrigan, CatherinePresident & CEODirectSell1216202570.743,225228,1325,951,530Form
2Corrigan, CatherinePresident & CEODirectSell1118202570.394,900344,8985,872,354Form
3Corrigan, CatherinePresident & CEODirectSell1016202566.824,930329,4405,529,855Form
4Corrigan, CatherinePresident & CEODirectSell916202569.914,905342,9035,785,161Form
5Corrigan, CatherinePresident & CEODirectSell815202571.094,896348,0435,782,370Form